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Between 1988 and 1991,26 episodes of bacteremia due to viridans streptococci occurred in 25
neutropenic patients undergoing intensive chemotherapy for hematologic malignancies. Compli-
cations related to the bacteremia were observed in 10 episodes: unilateral pulmonary infiltrates
(4), acute respiratory distress syndrome (ARDS) (4), hypotension (3), and endocarditis (2). All
patients with ARDS had received high doses of cytosine arabinoside and had bacteremia due to
Streptococcus mitis. Death occurred in three patients (12%) but was possibly related to bacter-
emia in only one case. Case patients who had received prophylaxis with quinolones were com-
pared with matched control patients who received similar prophylaxis but who did not have
bacteremia due to viridans streptococci. Multivariate analysis of predisposing factors showed
that high doses of cytosine arabinoside (P = .01), the presence of mucositis (P = .02), and the
absence of previous therapy with parenteral antibiotics (P = .01) were independent risk factors
for the development of viridans streptococcal bacteremia. Of 259 patients who had received
quinolone prophylaxis during the study period, 22 (8.5%) developed an episode ofviridans strep-
tococcal bacteremia as compared with three episodes (3.7%) in 82 patients who had received a
quinolone and penicillin (P = .07). However, the latter three episodes were caused by strains with
decreased susceptibility to penicillin, thus suggesting that resistance to penicillin might limit the
use of this antibiotic as a prophylactic agent in the future.
Viridans streptococci are an increasing cause of bacter-
emia in neutropenic patients with cancer [1-4]. The clinical
course may include adult respiratory distress syndrome
(ARDS) and shock that can be fatal. Case-control studies
have suggested that oral mucosal lesions are the most proba-
ble portal of entry [5-7] for viridans streptococci that cause
bacteremia and have identified predisposing factors such as
the use of high doses of cytosine arabinoside [6, 8], prophy-
laxis with quinolones [6], and antacids [7]. However, most of
these studies suffered from several methodological problems
including a limited number of patients [5], absence of con-
trol patients matched for the severity of neutropenia [7], im-
precise period of observation for risk factors [5-8], and lack
of data on colonization [6-8]. The purpose of the present
study was threefold: to review all the cases of viridans strep-
tococcal bacteremia that had occurred at our institution be-
tween 1988 and 1991, to assess risk factors in a case-control
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study with control patients matched for sex, age, underlying
disease, duration and severity of neutropenia, and quinolone
prophylaxis, and to assess the effect of penicillin added to
quinolone prophylaxis on colonization with and bacteremia
due to viridans streptococci.
Materials and Methods
Selection Criteria
We reviewed the episodes ofviridans streptococcal bacter-
emia that occurred in adult neutropenic patients hospitalized
at the Centre Hospitalier Universitaire Vaudois (Lausanne,
Switzerland) from January 1988 to December 1991. In this
unit, blood for cultures is routinely obtained if the patient's
temperature rises above 38°C and also before initiation of
any antibiotic therapy. Empirical antimicrobial therapy is ini-
"tiated in cases of fever, unless the increase in temperature is
clearly related to transfer of blood products. The following
data were collected for each patient: age, gender, underlying
disease, antineoplastic therapy, duration and severity ofneu-
tropenia, antibacterial and antifungal prophylaxis, use ofant-
acids, colonization with viridans streptococci, mucocu-
taneous lesions, serology for herpes simplex virus, time to
onset of fever or bacteremia, antiinfective therapy, and clini-
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Figure 1. Episodes of viridans streptococcal bacteremia accord-
ing to the year ofoccurrence and the type ofan tibiotic prophylaxis.
R = resistant to penicillin (see text).
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cal status from the onset of the chemotherapy responsible for
the development of neutropenia until discharge or death.
Fever was defined as a temperature of at least 38°C sus-
tained for > 2 hours. Profound neutropenia was defined as a
granulocyte count of < 100 cells/rnrrr'. In all but five pa-
tients, for whom only one set of blood for culture was ob-
tained, the diagnosis of viridans streptococcal bacteremia
was established by the presence of two or more sets of blood
cultures positive for viridans streptococci.
Clinical Evaluation
ARDS was defined by the occurrence of tachypnea (respi-
ratory rate, >25/min), arterial hypoxemia (arterial oxygen
pressure, <60 mm Hg), and bilateral pulmonary infiltrates.
Shock was defined as a systolic pressure of <90 mm Hg and
oliguria.
Selection of Patients for Case-Control Study
Between 1988 and 1991, 26 episodes of viridans strepto-
coccal bacteremia occurred in 25 neutropenic patients un-
dergoing intensive chemotherapy for hematologic malignan-
cies (one patient had two episodes of bacteremia, each
during a different episode of neutropenia). In 22 of these 26
episodes, patients had received a quinolone alone for antibac-
terial prophylaxis and were selected as case patients for a
case-control study evaluating risk factors. For each case pa-
tient, one control patient was matched for sex, age ±5 years,
underlying neoplasia, antimicrobial prophylaxis, and sever-
ity and duration of neutropenia. Control patients did not
have bacteremia.
Evaluation of Predisposing Factors
Risk factors were evaluated during a period starting from
the onset of chemotherapy until the occurrence of bacter-
emia for case patients and from the onset of chemotherapy
and during a matched period of observation for control pa-
tients. Risk factors included all findings that suggested infec-
tion, bleeding, or chemotherapy-induced toxicity. Sinusitis
was defined by clinical and radiographic signs. Vomiting was
defined as several episodes of vomiting that persisted for ~3
consecutive days. Diarrhea was defined as several daily loose
stools that persisted for ~3 consecutive days. Clinically docu-
mented esophagitis was defined as gastric or esophageal pain
after exclusion of cardiac ischemia. High doses of cytosine
arabinoside were defined as > 3 g/m2 every 12 hours.
frame of a new protocol of antimicrobial prophylaxis. A sec-
ond case-control study was performed for evaluating the ef-
fect of prophylaxis with penicillin on colonization with viri-
dans streptococci. In this second study, the control patients
of the first study who were receiving prophylaxis with a quin-
olone alone were matched with similar neutropenic patients
receiving penicillin prophylaxis with a quinolone. The selec-
tion criteria were the same as those of the first study.
Microbiology
Specimens of urine and from the nose, mouth/throat,
anus, and any suspected area were obtained twice a week for
body surveillance cultures. In the presence of fever, speci-
mens of blood and urine and from any suspected site of in-
fection were obtained for culture. Viridans streptococci and
the species level were identified according to standard meth-
ods [9], and their susceptibility to quinolones and penicillin
was assessed by disk diffusion according to the criteria of the
NCCLS (National Committee for Clinical Laboratory Stan-
dards, 1990) [10].
Statistical Analysis
Differences between categorical variables were tested for
significance by the two-tailed Fisher's exact test. A multivar-
iate logistic regression analysis of risk factors was performed
with the use of maximal likelihood estimators of the logistic
model. A P value of <.05 was considered significant.
Effect of Penicillin on Colonization with Viridans Streptococci
Because of the increasing number of cases of viridans
streptococcal bacteremia, since 1989 penicillin has been
added to quinolone prophylaxis for certain patients in the
Results
Epidemiology
Between 1988 and 1991, 341 episodes of profound neu-
tropenia were observed. Of these episodes, 87 were asso-
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ciated with bacteremias, of which 64 (74%) were due to
gram-positive cocci; 12 (14%), gram-negative bacilli; 8 (9%),
fungi; and 3 (3%), anaerobes. Among the 64 bacteremias due
to gram-positive microorganisms, 26 (41 %) were caused by
viridans streptococci, which were the most prevalent bactere-
mic organisms (figure 1), accounting for 30% of all bacter-
emias. The bacteria identified by blood cultures were Strep-
tococcus mitis in 15 episodes (58%) and Streptococcus sanguis
II in 11 (42%). Three of the S. sanguis II strains were eventu-
ally reclassified as S. oralis. For one patient, blood cultures
were positive for both S. sanguis and Staphylococcus epider-
midis.
Prophylactic antibacterial agents were a quinolone in 259
episodes of neutropenia and a quinolone and penicillin in
82. Under quinolone prophylaxis, 22 episodes (8.5%) ofviri-
dans streptococcal bacteremia were observed as compared
with only 3 (3.7%) under prophylaxis with a quinolone and
penicillin (P = .07). All viridans streptococci isolated from
blood cultures were resistant to the quinolone given as pro-
phylaxis. Twenty-two strains (85%) were susceptible to peni-
cillin, two were intermediate, and two were resistant. Three
of the patients from whom intermediate or resistant strains
were isolated were receiving penicillin prophylaxis at the
time ofbacteremia. The MICs ofpenicillin were 0.5,4, and 4
JLg/mL, respectively, for these three patients' strains.
General Characteristics of the Patients
The characteristics of the case patients and their control
patients are given in table 1. The median age of the patients
in the 26 episodes of bacteremia was 41.3 years (range, 17-
76 years), and there were 17 men and 9 women. Fifteen
patients (58%) had acute nonlymphocytic leukemia, 5 (19%)
had acute lymphocytic leukemia, 2 (8%) had Hodgkin's dis-
ease, 2 (8%) had non-Hodgkin's lymphomas, and 2 (8%) had
multiple myelomas. Two patients had undergone autologous
bone marrow transplantation. Among the 20 patients with
leukemia, 2 had received first induction chemotherapy, 7
had received chemotherapy for relapse, and 11 were receiv-
ing maintenance chemotherapy. All patients were pro-
foundly neutropenic at the time of bacteremia. The 26 epi-
sodes of bacteremia occurred after a median duration of29.8
days of hospitalization (range, 9-82 days) and 6.4 days
(range, 1-12 days) of profound neutropenia.
No patients were receiving parenteral antibiotics when bac-
teremia occurred, but oral antibacterial prophylaxis had
been given to all patients for a median duration of 11.6 days
(range, 3-28 days). Prophylaxis consisted of a quinolone in
22 patients (85%) and a quinolone with penicillin in 3 (12%).
In one case (4%), prophylaxis with a quinolone was stopped
3 days before the onset of bacteremia because of presumed
allergy. The quinolones used were norfloxacin (400 mg bid)
in 15 patients (58%), pefloxacin (400 mg bid) in 9 (35%), and
ciprofloxacin (500 mg bid) in 1 (4%).
Clinical Conditions Associated with Viridans Streptococcal
Bacteremia
At the time of bacteremia, fever was observed in 25 epi-
sodes (96%). In the afebrile episode, bacteremia was docu-
mented after gastroscopy. Chills were associated with 13 epi-
sodes (50%). Four patients developed a rash I to 5 days after
the bacteremia; drug allergies could not be excluded as the
cause of the rash in these patients.
Hypotension. Three patients ( 12%)had hypotension that
was rapidly reversed by volume replacement.
Pulmonary infiltrates. Pulmonary infiltrates were noted
in eight episodes (30%). In four episodes ( 157(",), ARDS devel-
oped 3 to 4 days after the documentation of bacteremia.
Three patients had to be transferred to the intensive care
unit. All four patients had received high doses of cytosine
arabinoside and had S. mitis bacteremia. One episode was
due to a penicillin-resistant strain of S. mitis. All patients
with ARDS recovered. A unilateral pulmonary infiltrate was
observed in four episodes (15%), ofwhich two were due to S.
mitis and two were due to S. sanguis II. In one episode, it was
present on the day ofthe onset ofbacteremia and was consid-
ered as a possible portal of entry. In three episodes, it devel-
oped 5, 7, and 8 days after the onset of bacteremia, respec-
tively, and no microorganism was identified in the specimens
obtained by bronchoalveolar lavage.
Endocarditis. Two patients developed a new murmur.
and at presentation echocardiography revealed findings con-
sistent with endocarditis. One of the patients had had pre-
vious valvular abnormalities.
Treatment and Outcome
Initial treatment. All patients were treated with broad-
spectrum antibiotics. Initial empirical treatment was found
to be appropriate by in vitro susceptibility testing of the
bloodstream isolates in all episodes.
Clinical outcome. In 13 episodes (50%). the patients de-
fervesced within the first 4 days of therapy. In nine episodes
(35%), defervescence occurred only after 4 days. In four epi-
sodes (15%), no clinical response was observed until bone
marrow recovery (three episodes) or death (one episode).
Three patients ( 12%)died during the neutropenic episode. In
only one patient with uncontrolled leukemia was bacteremia
thought to have precipitated death.
Predisposing Factors
Comparison between case patients receiving quinolone pro-
phylaxis and control patients. Table 2 shows the predispos-
ing factors for viridans streptococcal bacteremia. The pro-
portion of case patients colonized with viridans streptococci
was higher than that of control patients (P < .05). Case pa-
tients presented with more mucocutaneous lesions than did
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Table 1. General characteristics of neutropenic cancer patients with bacteremia due to viridans
streptococcus.
Case-control study
Case Control
patients* patients
(n = 22) (n = 22)
42.9 (17-76) 38.7 (17-74)
13/9 13/9
17 (77) 17 (77)
5 (23) 5 (23)
I (4) I (4)
22 (100) 22 (100)
24.4 (10-60) 27.7 (13-51)
16.8 (7-43) 19.9 (4-48)
22 (100) 22 (100)
22 (100) 22 (100)
Patient characteristics
Median age in y (range)
Male/female ratio
No. (%) of patients with underlying neoplasia
Acute leukemia
Lymphoma or myeloma
No. (%) of patients who underwent autologous
bone marrow transplantation
Characteristics of neutropenia
No. (%) of patients with granulocyte counts
of <100/mm3
Median duration in d of count < 1.000/mm3
(range)
Median duration in d of count < I 00/mm3
(range)
No. (%) of patients who received oral antifungal
prophylaxis
Oral antibacterial prophylaxis
No. (%) of patients who received quinolones
No. (%) of patients who received quinolones
and penicillin
None
Duration in d of therapy (range)
Clinical study
Episodes
(n = 26)
41.3 (17-76)
17/9
20 (77)
6 (23)
2 (8)
26 (100)
26.1 (10-60)
17.7 (7-43)
26 (100)
22 (85)
3 (12)
I (4)t
11.6 (3-28) 11.6 (3-28) 12.7(2-23)
* Patients from the 26 episodes of bacteremia (shown in the first column) who were receiving prophylaxis with a
quinolone alone at the onset of bacteremia.
t Quinolone prophylaxis was stopped 3 days before the onset of bacteremia (patient was not selected as a case
patient).
control patients (P = .0 I), especially in the oral cavity. In
addition, case patients received high doses of cytosine ara-
binoside as part of their chemotherapy more often than did
control patients (P < .00 I). Among control patients, 13
(59%) had received antibiotics for empirical treatment of a
febrile episode during the matched period of observation. In
contrast, among case patients, only one (5%) had received
parenteral antibiotics before the onset of bacteremia (P <
.001), and this treatment had been stopped 8 days before the
onset of bacteremia.
Multivariate analysis of risk factors showed that three fac-
tors were independent predictors for the development ofviri-
dans streptococcal bacteremia: absence of parenteral anti-
biotherapy during the observation period (P = .01), high
doses of cytosine arabinoside as part of the chemotherapy (P
= .01), and the presence of oral mucositis (P = .02).
Effect of Penicillin on Colonization with Viridans Streptococci
Comparison of patients who had received a quinolone
alone (control patients for the first case-control study) with
matched control patients who had received a quinolone and
penicillin revealed that penicillin did not decrease coloniza-
tion with viridans streptococci (table 3). Colonization at the
oropharyngeal site was even higher in patients receiving pen-
icillin (P < .05).
Discussion
Viridans streptococci have become an increasingly com-
mon cause of bacteremia in patients undergoing intensive
chemotherapy. Recent studies revealed that viridans strepto-
cocci were responsible for 14% to 19% of the bacteremias in
adult patients with cancer [3, 11]. In our institution, viridans
streptococci were responsible for 30% of all bacteremic epi-
sodes in neutropenic adults hospitalized from 1988 to 1991
and were the most prevalent cause of bacteremia in this pa-
tient population. However, with the addition of penicillin to
the quinolone prophylaxis regimen, which has been increas-
ingly prescribed since 1989, a decrease in the incidence of
viridans streptococcal bacteremia was observed.
Clinically, most patients presented with only fever and
defervesced while receiving broad-spectrum antibiotics.
Complications were observed in 10 episodes (38%). In four
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Table 2. Predisposing factors for bacteremia.
No. (%) with characteristic
Case Control P value
patients patients (Fisher's
Patient characteristic (n = 22) (n = 22) exact test)
Body cultures positive for viridans streptococci" 20 (91) 15 (68) <05
Nose 3 (14) () NS
Oropharyngeal 16 (73) II (50) NS
Perianal 9 (41) 7 (32) NS
Skin t I (5) I (5) NS
Gastrointestinal fluid t I (5) I (5) NS
Mucocutaneous lesions 22 (100) 16 (73) <.01
Nose (sinusitis or epistaxis) 2 (9) 0 NS
Oropharyngeal 18 (82) 12 (55) 05
Mucositis 16 (73) 8 (36) <.05
Gingivitis 6 (27) 3 (14) NS
Oral candidosis 4 (18) 2 (9) NS
Dental procedures 0 I (5) NS
Perianal 2 (9) 2 (9) NS
Skin 2 (9) 4 (18) NS
Gastrointestinal (gastritis or esophagitis) 7 (32) 4 (18) NS
Other findings
Pulmonary infiltrate 2 (9) 3 (14) NS
Rash 8 (36) 5 (23) NS
Vomiting or diarrhea 9 (41) 5 (23) NS
Central intravenous catheter 22 (100) 22 (100) NS
Herpes simplex virus serology
(no. positive/no. performed) 13/18 (72) 10/19 (53) NS
Medications
High doses of cytosine arabinoside 14 (64) 3 (14) <001
Previous parenteral empirical therapy I (5) 13 (59) <001
Sucralfate 3 (14) 2 (9) NS
Antacids 5 (23) 3 (14) NS
H2 antagonists I (5) 2 (9) NS
Corticosteroids 7 (32) 7 (32) NS
Acyclovir 12 (55) 9 (41) NS
NOTE. Risk factors were evaluated during a period from the onset of chemotherapy until the occurrence of
bacteremia for case patients and from the onset of chemotherapy and during a matched period of neutropenia for
control patients. NS = not significant.
* Microbiological data missing for two case patients and one control patient.
t Performed only if lesion was present.
t Performed only if endoscopy was performed.
episodes (15%). patients developed ARDS secondary to bac-
teremia. but none died. A comparable incidence of ARDS
was observed by other investigators [3.7. 12. 13].The patho-
physiological events responsible for the development of
ARDS have not been clearly identified. Cytosine arabinoside
alone can cause a pulmonary toxic effect resembling ARDS
[14. 15]. Thus. it has been suggested that viridans strepto-
cocci trigger the development of noncardiogenic pulmonary
edema in patients with preexisting damage of the lung due to
aggressive cytotoxic treatment [16-18]. This suggestion is in
agreement with our study. since all patients who developed
ARDS and three of the four patients who developed pulmo-
nary unilateral infiltrates had received high doses of cytosine
arabinoside. The species of streptococci might also playa
role in the development of ARDS [7]. In the present study.
all the patients with ARDS were infected by S. mitis. thereby
suggesting that this bacteria may be more prone to cause
ARDS than the other species of viridans streptococci.
In our series. three patients developed hypotension. but
none of the patients had true shock. Two patients developed
signs consistent with endocarditis. which has also been re-
ported by other investigators [7].
Only three patients ( 12[+) died during the neutropenic epi-
sode. However. bacteremia appeared to plav a contributory
role in only one death. In other studies. a mortality rate of
II %to 22% has been reported [3. 6. 7].
Three factors were found to predict the occurrence ofviri-
dans streptococcal bacteremia. The first factor was the pres-
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Table3. Effect of penicillin prophylaxis on colonizationwith viridans streptococci.
No. (%) with characteristic
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Patient characteristic
Body site cultures positive
for viridans streptococci!
Nose
Oropharyngeal
Perianal
Skin;
Gastrointestinal fluids!
Mucocutaneous lesions
Nose (sinusitis or epistaxis)
Oropharyngeal
Perianal
Skin
Gastrointestinal (gastritis or esophagitis)
Patients treated
with a quinolone*
(n = 22)
14 (64)
o
II (50)
7 (32)
I (5)
I (5)
16(73)
o
12(55)
2 (9)
4 (18)
4 (18)
Patients treated with
a quinolone and
penicillin
(n = 22)
17 (77)
I (5)
17 (77)
4 (18)
I (5)
I (5)
16 (73)
2 (9)
15 (68)
o
8 (36)
4 (18)
P value
(Fisher's
exact test)
NS
NS
<.05
NS
NS
NS
NS
NS
NS
NS
NS
NS
NOTE. NS = not significant.
* Control patients of the first case-control study.
t Microbiological data missing for one patient treated with quinolone and for two patients treated with quino-
lone and penicillin.
; Performed only if lesion was present.
§ Performed only if endoscopy was performed.
ence of mucositis. Several authors have suggested that oro-
pharyngeal lesions were the most probable portal ofentry for
viridans streptococci that cause bacteremia [1, 3, 5-7]. This
suggestion is consistent with the present case-control study
in which a higher rate of oropharyngeal colonization with
viridans streptococci was found among patients with bacter-
emia than among control patients. However, three of our
cases suggest that the rest of the digestive tract, particularly
the stomach, and the lower respiratory tract might also be
occasional portals of entry.
Second, patients with viridans streptococcal bacteremia
had significantly more often received high doses of cytosine
arabinoside as part of their chemotherapy, thereby confirm-
ing results of previous studies [6, 16, 17, 19]. This finding
suggests that high doses of cytosine arabinoside may playa
role in the development of viridans streptococcal bacter-
emia. Thus, viridans streptococcal bacteremia may have be-
come more common because of the increasing use of this
form of chemotherapy [17].
Third, the absence of parenteral antibiotics during the ob-
servation period was another factor significantly associated
with the occurrence of viridans streptococcal bacteremia.
Thus, broad-spectrum antibiotics prescribed early in the
course of the neutropenic episode of the control patients for
empirical treatment ofa fever probably protected them from
viridans streptococcal bacteremia. Inde-ed, viridans strepto-
coccal bacteremia was found to occur only after a median
duration of 6.4 days of profound neutropenia. Since many
neutropenic patients develop a febrile episode earlier in the
course of neutropenia, they receive parenteral broad-spec-
trum antibiotics for empirical treatment. In the present
study, such treatment was received by 59% of the control
patients during the matched period of observation. It is un-
likely that the febrile episodes observed in control patients
were related to undiagnosed viridans streptococcal bacter-
emia since blood for cultures is routinely obtained in cases of
fever.
Because of their effectiveness in preventing infections due
to gram-negative organisms, the fluoroquinolones are fre-
quently used as prophylaxis for patients with cancer. Viri-
dans streptococci are typically resistant to these antibiotics
[20, 21], and bacteremia due to these microorganisms has
been observed under this prophylactic regimen [1, 2,
6-8,22].
The above-mentioned reasons are why since 1989 penicil-
lin has been added to quinolones in the prophylactic regimen
ofsome patients in the frame ofa new protocol ofantimicro-
bial prophylaxis. This addition resulted in the progressive
decrease in the number ofcases ofviridans streptococcal bac-
teremia observed in our institution. However, three cases
were observed while the patients were receiving prophylaxis
with a quinolone and penicillin. In all three cases, the strains
were relatively resistant to penicillin. When patients receiv-
ing a quinolone alone were compared with matched patients
receiving a qui nolone with penicillin, no difference was
found in the incidence of colonization with viridans strepto-
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cocci, thus suggesting that penicillin prevents viridans strep-
tococcal bacteremia but not colonization with viridans strep-
tococci. Therefore, wide and prolonged use of penicillin may
induce the development of resistance in a patient and possi-
bly in the community, which could affect the efficacy ofpen-
icillin prophylaxis as suggested by the three patients who
developed viridans streptococcal bacteremia while receiving
a quinolone and penicillin.
In conclusion, viridans streptococci have been an increas-
ing problem in neutropenic patients. This problem is proba-
bly related to the use of quinolones as antibacterial prophy-
laxis [1, 2, 6-8, 22]. Our study has identified the use of high
doses of cytosine arabinoside, the presence of mucositis, and
the absence of previous parenteral antibiotics as risk factors
for the development of viridans streptococcal bacteremia.
The adjunction ofpenicillin to a quinolone as a prophylactic
agent appears to confer protection against viridans strepto-
cocci bacteremia but does not prevent colonization with the
organisms. Therefore, penicillin might select for resistant
strains and become ineffective in a given patient or patient
population.
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